Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Short term Debt (2021 - 2024)

Historic Short term Debt for Ascendis Pharma A (ASND) over the last 5 years, with Q3 2025 value amounting to $273.3 million.

  • Ascendis Pharma A's Short term Debt rose 4781.38% to $273.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.3 million, marking a year-over-year increase of 4781.38%. This contributed to the annual value of $163.1 million for FY2024, which is 577.13% up from last year.
  • Ascendis Pharma A's Short term Debt amounted to $273.3 million in Q3 2025, which was up 4781.38% from $211.2 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Short term Debt peaked at $273.3 million during Q3 2025, and registered a low of $8.0 million during Q4 2021.
  • Over the past 5 years, Ascendis Pharma A's median Short term Debt value was $159.8 million (recorded in 2022), while the average stood at $152.8 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Short term Debt skyrocketed by 191382.77% in 2022, and later crashed by 2406.51% in 2023.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Short term Debt stood at $8.0 million in 2021, then soared by 1913.83% to $161.1 million in 2022, then fell by 4.33% to $154.2 million in 2023, then rose by 4.43% to $161.0 million in 2024, then surged by 69.73% to $273.3 million in 2025.
  • Its Short term Debt was $273.3 million in Q3 2025, compared to $211.2 million in Q2 2025 and $183.6 million in Q1 2025.